CoChat

The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes

Open access
Beck, George R., Khazai, Natasha B., Bouloux, Gary F., Camalier, Corinne E., Lin, Yiming, Garneys, Laura M., Siqueira, Joselita, Peng, Limin, Pasquel, Francisco, Umpierrez, Denise, Smiley, Dawn, Umpierrez, Guillermo E. · 2013 · Translational Research
Cited by 61

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Thiazolidinedione (TZD) therapy has been associated with increased risk of bone fractures. Studies in rodents have led to a model in which decreased bone quality in response to TZDs is due to a competition of lineage commitment between osteoblasts and adipocytes for a common precursor cell resulting in decreased osteoblast numbers. Our goal was to investigate the effects of TZD exposure on osteoblast-adipocyte lineage determination from primary human bone marrow stromal cells (hBMSCs) both in vitro and in vivo from non-diabetic subjects and patients with type 2 diabetics. Our experimental design included two phases. Phase 1: An in vitro study of TZDs effects on hBMSCs differentiation into osteoblasts and adipocytes in non-diabetic subjects. Phase 2: a randomized placebo controlled trial to determine the effects of six month pioglitazone treatment in vivo on hBMSC differentiation using adipocyte/osteoblast colony forming unit assays in patients with type 2 diabetes. In vitro, TZDs (pioglitazone and rosiglitazone) enhanced adipogenesis of hBMSCs while neither altered osteoblast differentiation and/or function as measured by alkaline phosphatase activity, gene expression, and mineralization. The ability of TZDs to enhance adipogenesis occurred at a specific time/stage of the differentiation process and pre-treating with TZDs did not further enhance adipogenesis. In vivo, six month TZD treatment decreased osteoblast precursors, increased adipocyte precursors, and increased total colony number in patients with type 2 diabetes. Our results indicate that TZD exposure in vitro potently stimulates adipogenesis but does not directly alter osteoblast differentiation/mineralization or lineage commitment from hBMSCs. TZD-treatment in type 2 diabetic patients however results in decreased osteoblastogenesis from hBMSCs compared to placebo indicating an indirect negative effect on osteoblasts suggesting an alternative model by which TZDs might negatively regulate bone quality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.trsl.2012.08.006

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 61

Metadata

Authors
Beck, G. R., Khazai, N. B., Bouloux, G. F., Camalier, C. E., Lin, Y., Garneys, L. M., Siqueira, J., Peng, L., Pasquel, F., Umpierrez, D., Smiley, D., & Umpierrez, G. E.
Venue
Translational Research
Publisher
Elsevier BV
Published
2013-03
Volume
161
Issue
3
Pages
145-155
ISSN
  • 1878-1810 (ISSN-L)
  • 1931-5244
OpenAlex
W1990354436
Cited by
61
References
8
FWCI
2.44
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. https://app.cochat.ai/papers/10.1016/j.trsl.2012.08.006
The paper
Beck, G. R., Khazai, N. B., Bouloux, G. F., Camalier, C. E., Lin, Y., Garneys, L. M., Siqueira, J., Peng, L., Pasquel, F., Umpierrez, D., Smiley, D., & Umpierrez, G. E. (2013). The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Translational Research. https://doi.org/10.1016/j.trsl.2012.08.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.